DIetary plAnt Extracts, Colonic MicrObes, and Apoe geNetics Interactions stuDy
NCT ID: NCT05905822
Last Updated: 2025-11-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
49 participants
OBSERVATIONAL
2023-06-19
2025-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease
NCT04693520
Ageing Gut Brain Interactions
NCT03593941
Non-pharmacological Intervention for Preclinical Alzheimer's Disease
NCT04279418
A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease
NCT02912936
APOE in the Predisposition to, Protection From, and Prevention of Alzheimer's Disease
NCT04994847
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Nutrition is considered important for brain function throughout life, and findings from recent laboratory and human observational studies have suggested that reactive compounds extracted from edible plants (dietary bioactives) can not only improve brain function, but they can change the function and composition of gut bacteria. Dietary bioactives are a range of natural compounds found in great concentrations within fruits and vegetables which influence the body. An example of a dietary bioactive is a group of compounds known as polyphenols. These polyphenols are described as antioxidants and are found in various foods, including berries, tea, and cocoa.
There have been no previous studies looking at the impact of dietary bioactives on the microbiome of each APOE genotype and the metabolites produced by each of these bacteria. We aim with the current study to identify how dietary bioactives from a range of plant tissue could influence gut bacteria present and the metabolites produced by the bacteria in each APOE group, and the compounds produced by these bacteria.
What will the study involve? Once we have established a potentially suitable participant, they will be sent a salivary sampling kit. Depending on the genotype, age and sex, participants will be requested to donate a stool sample. The stool will be processed in a colon model with cocoa polyphenol added.
The study involves the following stages:
1. Online screening, consenting, and collection of basic information
2. Collection of a salivary sample in person at the Clinical Research Facility or home and return to the labs via pre-paid postal mail.
3. Confirmation of eligibility to donate stool samples.
4. Collection of stool samples on the same day as sample collection. Returning the sample in person or through the pre-paid postal system.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Prospectively genotyped participants
These participants will be advertised to in the local area. They will be genotyped for their APOE genotype, and then the stool sample will be collected.
No interventions assigned to this group
Database participants
Participants from the previously genotyped cohort "Early sleep and circadian markers of Alzheimer's disease: the impact of APOE-ε4 on circadian rhythm and sleep-wake homeostasis in humans" (Reference: 2017/18-135) who have consented to be contacted will be contacted to collect a stool sample.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Fluent in written and spoken English and capacity to consent
* Availability to take part in the study
Exclusion Criteria
* They will also be excluded if they have a diagnosis of any form of dementia or severe cognitive impairment.
* They currently consume a high flavonoid intake defined as \>15 portions of flavonoid rich food per day.
* History or MRI evidence of brain damage, including significant trauma, stroke, learning difficulties or serious neurological disorder, including a loss of consciousness for more than 24 hours.
* Currently smoking or ceased smoking less than 6 months ago.
* Chronic fatigue syndrome, liver disease, diabetes mellitus, or gall bladder abnormalities.
* History of alcohol or drug dependency.
* Clinically diagnosed psychiatric disorder.
* Currently a participant or have been a participant in any other study involving an investigational product within the last 4 weeks.
* Received a COVID-19 diagnosis within the last 30 days
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Quadram Institute Bioscience
OTHER
University of East Anglia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Vauzour, PhD
Role: PRINCIPAL_INVESTIGATOR
University of East Anglia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Norwich and Norfolk University Hospital Clinical Research Facility
Norwich, Norfolk, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Raulin AC, Doss SV, Trottier ZA, Ikezu TC, Bu G, Liu CC. ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies. Mol Neurodegener. 2022 Nov 8;17(1):72. doi: 10.1186/s13024-022-00574-4.
Seals RR Jr, Morrow RM, Kuebker WA. The dentist's role in Texas high school mouthguard programs. Tex Dent J. 1984 Oct;101(10):6-9. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
319832
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.